Abstract: The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof.

Abstract: Provided is a gel composition including a partial degradation product of the galactose moiety of galactoxyloglucan, a compound that is a mixture of one kind or two or more kinds selected from magnesium salt, calcium salt, aluminum salt, and sodium salt, and an aqueous solvent.

Abstract: The present invention includes pourable, non-toxic lubricating compositions containing carrageenan and more precisely ? carrageenan as an anti-viral agent, for protection from Human Papillomavirus (HPV), and methods of using the lubricating compositions as a non-oily, psuedoplastic lubrication product and administering the carrageenan for reducing the propagation of HPV during sexual activity.

Abstract: Solid stick antiperspirant compositions include an antiperspirant active, one or more waxes, and a plurality of liquids. The one or more waxes include a polar wax. The plurality of liquids include about 60% or greater, by weight of the plurality of liquids, of a non-volatile silicone. The solid stick antiperspirant composition is substantially or completely free of volatile silicones. Antiperspirant product containing solid stick antiperspirant compositions are also described herein.

Abstract: Disclosed herein is a device and method for regenerating tissue using a modular scaffold having a gradient of enzymatic degradability. The disclosure further relates to scaffolds made of microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof.

Abstract: The present invention relates to a gastric retention active delivery system in the form of a coated capsule, which, in contrast to prior art delivery systems exhibiting relatively poor floating-properties, and thus requiring size expansion capability in order to securely delay passage through the pylorus, reliably stay afloat for several hours. This is achieved by combining pore forming components and flexible polymer components in the coating in suitable proportions. The present invention, further, relates to the use of gastric retention active delivery systems of the invention for the delivery of one or more water soluble active components A to a mammal.

Abstract: Disclosed are applications of a mussel adhesive protein or preparations thereof in treatment and prevention of diseases related to melanin. Specifically disclosed are applications of a mussel adhesive protein or preparations thereof in treatment and prevention of pigmentations such as chloasma, freckles, melanosis, applications in skin cancers represented by melanoma, and applications in treatment of pigmentation possibly caused by skin diseases or drugs.

Abstract: A composition for the enhancement of free testosterone is provided, the composition comprising: vitamin B6; vitamin B12; zinc; L-citrulline; fenugreek seed extract; an adenosine triphosphate (ATP) stimulating component, comprising: ancient peat extract, and apple fruit extract; eurycoma root extract; and boron. A method of increasing free testosterone is provided, the method comprising administering to an individual an effective dose of a composition comprising: vitamin B6; vitamin B12; zinc; L-citrulline; fenugreek seed extract; an adenosine triphosphate (ATP) stimulating component, comprising: ancient peat extract, and apple fruit extract; eurycoma extract; and boron.

Abstract: The present invention relates to a solid makeup and/or care cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: one pulverulent phase, one organopolysiloxane elastomer, one emulsifying system, one hydrophilic gelling agent, and one organic non-volatile oil present in a content of greater than or equal to 1% by weight relative to the total weight of the composition. The invention also relates to an intermediate composition for the preparation of such a cosmetic composition, to a process for manufacturing this cosmetic composition, and to a process for coating the skin with the said cosmetic composition.

Abstract: This cellulose powder has: an average degree of polymerization of 100 to 350; a weight average particle size of over 30 ?m, but less than 250 ?m; an apparent specific volume of 2 to less than 15 cm3/g; and an organic carbon content from residual impurities, which is defined by the total organic carbon content (%) during 1% NaOH extraction to the total organic carbon content (%) during pure water extraction, of over 0.07 to 0.3%.

Abstract: A method of preventing or treating an eye condition includes administering a sterile aqueous ophthalmic solution to an eye for the prevention or treatment of dry eye syndrome or dry eye sign and/or dry eye symptom. The sterile aqueous ophthalmic solution includes about 0.05% to about 0.5% (w/w) of N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer.

Abstract: The instant disclosure relates to anhydrous hair-treatment compositions. The anhydrous hair-treatment compositions typically include one or more bis-urea derivatives, hydrophobic silica aerogel, and one or more solvents, for example, ester oils and non-ester oil solvents. Additional components such as silicones, etc., can also be included. Kits comprising the hair-treatment compositions and methods of using the hair-treatment compositions are also disclosed.

Abstract: The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.

Abstract: Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided.

Abstract: Among others, the present invention provides a blank liposome, preparation methods thereof, and a loaded liposome including the blank liposome and an active substance. The liposomes have a membrane comprising lipids and a ginsenoside of Formula I, and may further comprise a surfactant, a heat-sensitive excipient, a pH sensitive material, or an ion additive.

Abstract: Metal free antimicrobial and UV protection additives, which can be used in building or finishing materials, such as plasters, mortars, primers, paints and other protective or decorative coatings to eliminate growth of bacteria, fungi, algae and lichen and to protect material from ultraviolet (UV) radiation. The additive having mixed organophilic layer illite-smectite, chlorite, illite, carbonates, silica and hematite with the following ratio of the components (weight %): mixed layer organophilic illite-smectite from 40 to 70%; chlorite from 5 to 10%; illite from 5 to 10%; carbonates from 0 to 20%; silica from 5 to 20%; hematite from 0 to 3%. The mixed layer illite-smectite is organophilized with quaternary ammonium compounds used in the amount from 10 to 30% counting from the required weight of the mixed layer organophilic illite-smectite.

Abstract: This disclosure provides a microencapsulated capsule or microparticle comprising a nutrient-filled core encapsulated in an enteric coating. The microparticles are useful in the treatment of a variety of disorders when ingested or administered to a subject in need thereof. Alternate non-encapsulated methods and compositions for providing the desired intestinal release are provided included modified nutrient composition and matrix embedded nutrient.

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Abstract: The present invention relates to a composition comprising one or more quaternary ester ammonium compounds (a), one or more amidoamine compounds (b), wherein the weight ratio between the one or more quaternary ester ammonium compounds (a) and the one or more amidoamine compounds (b) is within a range of 1:5 to 5:1, and one or more fatty alcohols (c). The present invention also relates to a composition that is solid at room temperature, to a hair conditioner composition and to a method to prepare the hair conditioner composition by dispersing the solid composition in water at moderate temperatures.

Abstract: An intraocular lens inserter for use during cataract surgery for delivering an intraocular lens (IOL) loaded into an IOL cartridge into a patient's eye. The inserter comprises an outer shell housing containing a hydraulic housing. A hydraulic piston positioned within the hydraulic housing defines an annular hydraulic chamber. The hydraulic chamber is filled with a fluid via a fill port. A high pressure compression spring constantly urges the piston forwardly to pressurize the fluid in the hydraulic chamber. During use, a valve element operatively connected to a depressible operation button, controls bleeding of fluid from the hydraulic chamber, whereupon the forward tip of the piston is moved forwardly to mechanically deliver the intraocular lens from the IOL cartridge into the patient's eye.

Abstract: Disclosed herein is a formulation for mitigating brain trauma including, in some embodiments, one or more ?-3 fatty acids, one or more curcuminoids, trans-resveratrol, ?-glycerylphosphorylcholine (“?-GPC”), and uridine-5?-monophosphate (“UMP”). The formulation is an oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, the trans-resveratrol, the ?-GPC, and the UMP for oral administration. Also disclosed herein is a packaged formulation for mitigating brain trauma including, in some embodiments, a sealed pouch containing a single dose of the oil-based emulsion including the one or more ?-3 fatty acids, the one or more curcuminoids, trans-resveratrol, ?-GPC, and UMP.

Abstract: The present invention relates to cosmetic compositions comprising a combination of at least one triazine compound of general formula (I): wherein A, B, X and R are as defined in the description, with other cosmetic sunscreens.

Abstract: A water-based fragrance composition comprises at least about 67 wt % water and between about 5 and about 17 wt % of a first organic solvent, wherein the first organic solvent comprises one or more relatively volatile, water soluble, low molecular weight organic compound(s) having a boiling point less than about 100° C. The water-based fragrance composition further comprises about 5 wt % or less of at least one fragrance formulation and between about 0 and about 22 wt % of a second organic solvent, wherein the second organic solvent comprises one or more moderately volatile, water soluble organic compound(s) having a boiling point greater than or equal to about 100° C. and less than or equal to about 300° C.

Abstract: The invention discloses a method of treating, preventing or ameliorating tumor or symptoms resulting from defective neurofibromatosis type-2 gene in a subject by administering to the subject a therapeutically effective amount of a ubiquitin-proteasome system inhibitor which inhibits or slows the growth of neurofibromatosis type-2-deficient tumor or associated symptoms. The invention also includes methods of diagnosis and screening of patients for neurofibromatosis type-2 and mesothelioma.

Abstract: The present invention provides that exosomes from human body fluid samples contain double stranded genomic DNA that spans all chromosomes and may be used to determine the mutation status of genes of interest in diseases, such as cancer. Furthermore, the present invention provides the use of exosomes to produce therapeutic proteins and for their use in therapy as well as the detection of cancer cell-derived exosomes to diagnose cancer and monitor therapeutic response.

Abstract: Disclosed herein are oil-in-water dispersions and sunscreen compositions that contain them, which exhibit high in vivo sun protection factor (SPF) efficiency due to the ability of the dispersions to both absorb and scatter ultraviolet (UV) light. These high efficiency sunscreen compositions include discrete oil particles that are enclosed within a solid coating and dispersed in an aqueous phase, wherein each oil particle contains an organic ultraviolet A (UVA) and/or an organic ultraviolet B (UVB) absorbing compound, and optionally a photo stabilizer.

Abstract: The present invention provides a water continuous dispersion of nanoparticles. The water continuous dispersion includes: one or more aromatic amide anesthetic compounds; one or more polyethoxylated high HLB surfactants; one or more low HLB surfactants; one or more oils, wherein one or more nanoparticles of a dispersed phase include a lipid bilayer, and wherein ratio of oil to surfactant is between about 0.12:1 to about 3.5:1. Methods of preparing various water continuous dispersion of nanoparticles are also provided.

Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Abstract: The present invention relates to the use of liver-selective glucokinase activators and a GLP1 analog in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.

Abstract: This invention relates to molecule and methods of treating diseases and disorders utilizing a Compound: ((3bS)-7-hydroxy-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl N-[(2S,3S,6R)-3-hydroxy-2-methyl-6-{[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl]carbamate) and pharmaceutically acceptable salts, hydrates, solvates, clathrates, prodrugs and polymorphs thereof. The present invention encompasses the in vitro and in vivo use of the said compound and the incorporation of the said compound into pharmaceutical compositions for the treatments and preventions of a variety of diseases and disorders.

Abstract: The present invention relates to a topical preparation for skin tissue protection and reparation. The complex preparation includes the following components: (1) polyethylene glycol; (2) water; and (3) flavonoid compound. The complex preparation may: (1) repair skin injury or promote wound healing; (2) eliminate scars; (3) prevent or treat skin injury caused by radiotherapy; and (4) prevent or treat radiodermatitis.

Abstract: Provided herein is a method for determining the bioavailability of a metal ion in a composition comprising a source of the metal ion, wherein the metal ion has antimicrobial activity, and wherein the method comprises: a) incubating a sample of the composition with bacterial cells, and b) determining the viability of the bacterial cells after incubation. The method is useful for determining the effect of agents on the bioavailability of metal ions in a composition.

Abstract: The invention relates to a solid composition in the form of a water-in-oil emulsion comprising, in a cosmetically acceptable carrier: (i) at least one discontinuous aqueous phase, (ii) at least one fatty phase comprising at least one particular wax, (iii) at least one silicone emulsifier selected in the group consisting in alkyldimethicone copolyols of particular formula (I) and dimethicone copolyols of particular formula (II) and mixtures there of (iv) and at least one antiperspirant active agent and/or one deodorant active agent. The invention relates to a method for treating body odours associated with human perspiration, and in particular body odours which are especially underarm odours. The invention relates to a method for preparing a solid composition in the form of a water-in-oil emulsion as defined above.

Abstract: The present invention relates to a solid pharmaceutical composition of temozolomide that has good and consistent flowability as a powder and taste masking and is readily dispersible in an aqueous solution suitable for oral administration, e.g., as a dry sprinkle. This permits patients and healthcare workers to accurately measure doses and safely dispense the drug.

Abstract: A cosmetic composition suitable for topical application is provided. The cosmetic composition comprises: glycerin; a lipid bilayer structurant with a glyceryl headgroup; a penetration enhancer; and a skin care active. The penetration enhancer increases the amount of active that enters skin when the composition is topically applied, while the glycerin and lipid bilayer structurant with glyceryl headgroup work together with lipid bilayers of the skin to impede progress of active through the skin.

Abstract: The present invention relates to a composition for improving the health status of various joints in the human body. The composition includes at least one plant extract as fatty base with active role, at least one extract from plants with anti-microbial properties, at least one extract from plants with analgesic and/or anti-inflammatory properties, and at least one extract from plants with anti-rheumatic and regenerative properties, to which dimethylsulfoxide, allantoin and/or potassium alum may be added. The composition may be used to treat osteoarthritis, rheumatic joint disease, joint swelling, pain, hallux valgus, traumatic conditions of the joints including sprains, strains, post-surgical recovery, bone edema, and speed up the recovery of athletes post-injury.

Abstract: The disclosure relates to dialkyl carbonates of branched alcohols and their use in cosmetic and/or pharmaceutical compositions. The disclosure more particularly relates to dialkyl carbonates in which the alkyl groups are both 2-propyl-1-heptyl groups.

Abstract: A deodorant stick comprising: at least about 25% of a liquid triglyceride; at least one antimicrobial; a primary structurant with a melting point of at least about 50° C.; and less than 8% of secondary structurants having a melting point of at least about 60° C.; said stick being free of an aluminum salt; and said stick having a hardness from about 80 mm*10 to about 140 mm*10, as measured by penetration with ASTM D-1321 needle.

Abstract: The present invention provided an apixaban solid composition and a preparation method thereof. The method comprises granulating apixaban by wet granulation, wherein the apixaban has a particle size D90 more than 89 ?m.

Abstract: A viscous composition for transdermal drug delivery, a method of preparing the same, and a microstructure device prepared using the viscous composition are provided. Here, the viscous composition includes colloidal particles formed of a combination of a drug and a biodegradable polymer, and the biodegradable polymer includes a first amphiphilic polymer. The use of a solvent can be minimized to homogenize the drug in the biodegradable polymer including the first amphiphilic polymer, thereby forming colloidal particles. Therefore, since a separate solvent cannot be used, the microstructure device is expected to be a transdermal drug delivery system which is safe, efficient or useful for drugs which do not include a proper solvent, show poor bioavailability or have a high molecular weight.

Abstract: Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, monitoring, and retrieving the same are provided.

Abstract: The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: The present invention provides a topical preparation for treating hyperhidrosis, comprising water, an anticholinergic drug, and one or more salts selected from the group consisting of lactate, tartrate, acetate and phosphate. Such a topical preparation comprises the above certain salt, thereby facilitating the accumulation of the anticholinergic drug in skin appendages.

Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.

Abstract: The present invention is directed to optical hydrogels, whose shape and/or refractive indices can be catalyzed by the application of light, methods of preparing the same, and optical devices and lenses derived therefrom.

Abstract: The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises inulin.

Abstract: An implantable device for improving or remedying valvular incompetence, comprising a sealing body and at least one anchoring element (2) fastened thereto, by means of which the sealing body is able to be fastened in the heart, preferably in the atrium of the heart, wherein the sealing body comprises at least one cavity (6), which is also able to be filled with a fluid after implanting the sealing body and preferably not able to be emptied independently, and wherein, furthermore preferably, the sealing body remains expanded with constant volume during the cardiac phases as a result of the filling, characterized in that a plurality of cavities (6) are disposed about a main body (1) of the sealing body lying in the direction of longitudinal extent of the sealing body, or a single cavity (6) surrounds a main body (1) of the sealing body lying in the direction of longitudinal extent of the sealing body, wherein the main body (1) is embodied as a tube which is able to be bent out of the linear extent thereof and in

Abstract: A system and method for predicting a health outcome of a user based on a determination of knowledge the user possesses regarding issues of physiological or mental health.